Celacade

{{Multiple issues|

{{Orphan|date=September 2023}}

{{notability|Products|date=January 2016}}

}}

Celacade was a non-drug, device-based treatment also known as Immune Modulation Therapy (IMT), developed by the Canadian-based biotherapeutics company Vasogen, Inc. for chronic heart failure and peripheral artery disease.{{cite journal |author=Visioli F |title=VasoCare. Vasogen |journal=Curr Opin Investig Drugs |volume=2 |issue=9 |pages=1247–9 |date=September 2001 |pmid=11717811 }}{{cite journal |title=Immune modulation therapy-peripheral vascular disease--Vasogen (VasoCare) |journal=Drugs in R&D |volume=3 |issue=5 |pages=358–60 |year=2002 |pmid=12455159 |doi= 10.2165/00126839-200203050-00013|s2cid=195340233 }} Blood was piped through the device, where it was exposed to heat, ultraviolet light, and ozone, in the hope that this oxidative stress would trigger an anti-inflammatory immunomodulation response.{{Cite book|last=Kumar|first=Soumitra|url=https://books.google.com/books?id=boJXDwAAQBAJ&q=celacade&pg=PA165|title=The Protocol Book for Intensive Care|date=2018-03-31|publisher=JP Medical Ltd|isbn=978-93-5270-305-0|pages=165–166|language=en}}{{cite journal|vauthors=Bulmer J, Bolton AE, Pockley AG|year=1997|title=Effect of combined heat, ozonation and ultraviolet irradiation (VasoCare) on heat shock protein expression by peripheral blood leukocyte populations|journal=J. Biol. Regul. Homeost. Agents|volume=11|issue=3|pages=104–10|pmid=9498159}}{{Cite book|last1=Tousoulis|first1=Dimitris|url=https://books.google.com/books?id=-R4bAAAAQBAJ&q=celacade&pg=PA380|title=Biomarkers in Cardiovascular Diseases|last2=Stefanadis|first2=Christodoulos|date=2013-07-29|publisher=CRC Press|isbn=978-1-4665-8714-4|pages=380|language=en}}

Despite some promising early results and one positive result in subgroup analysis, the technique usually did not produce the hoped-for clinically significant results.